Since it is unclear how well circulating IGF-1 levels reflect tissue-level GH/IGF-1 exposure, it is of clinical interest to ensure that long-term GHR antagonism has effects on bone that are comparable to other acromegaly therapies and does not oversuppress bone turnover or reduce aBMD, such as might occur with GH deficiency [19]. The gene discussed is GHR; the disease is acromegaly.